ES2100397T3 - Espiro(5.5)undecanos 3,9-disubstituidos activos sobre el sistema cardiovascular, proceso para su preparacion y composicion farmaceutica que contiene los mismos. - Google Patents

Espiro(5.5)undecanos 3,9-disubstituidos activos sobre el sistema cardiovascular, proceso para su preparacion y composicion farmaceutica que contiene los mismos.

Info

Publication number
ES2100397T3
ES2100397T3 ES93110193T ES93110193T ES2100397T3 ES 2100397 T3 ES2100397 T3 ES 2100397T3 ES 93110193 T ES93110193 T ES 93110193T ES 93110193 T ES93110193 T ES 93110193T ES 2100397 T3 ES2100397 T3 ES 2100397T3
Authority
ES
Spain
Prior art keywords
alkyl
opt
substd
undecans
espiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93110193T
Other languages
English (en)
Inventor
Marco Frigerio
Patrizia Ferrari
Piero Melloni
Giuliana Salani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2100397T3 publication Critical patent/ES2100397T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/36—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

3,9-SPIRO[5.5] UNDECANOS DISUSTITUIDOS DE FORMULA (I): EN LA QUE R REPRESENTA HIDROGENO O UN GRUPO ALKILO C2-C6 O ALKENILO C2-C6 SUSTITUIDO O INSUSTITUIDO, N ES UN NUMERO ENTERO DE 0 A 4 E Y ES OXIGENO O AZUFRE; Y EL SIMBOLO--CE SENCILLO O DOBLE SI (I) CUANDO -REPRESENTA UN GRUPO C-H O C-OR1 DONDE R1 ES H O CH3, Y B REPRESENTA UN A CADENA ALKILO INFERIO C2-C6 SUSTITUIDO O AKENILO C2-C6; (II) CUANDO -DE CARBONO C Y B REPRESENTA: A = GRUPO N-NR2-C(=Z)NHR3, DONDE R2 Y R3 SON HIDROGENO, ALKILO INFERIOR C1-C6, BENCILO O FENILO, O R2 Y R3, TOMADOS JUNTOS CON LOS ATOMOS DE NITROGENO, FORMAN UN ANILLO DE 5 O 5 MIEMBROS, Y Z ES OXIGENO, AZUFRE O NR9, DONDE R9 ES H,ALKILO INFERIOR C1-C4, CN O TOMADO JUNTO CON R2 O R3 FORMA UN ANILLO DE 5 O 6 MIEMBROS MONOHETEROCICLICO SUSTITUIDO; Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. ESTOS COMPUESTOS PUEDEN SER USADOS PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES, HIPERTENSION Y/O FALLO CARDIACO.
ES93110193T 1992-07-08 1993-06-25 Espiro(5.5)undecanos 3,9-disubstituidos activos sobre el sistema cardiovascular, proceso para su preparacion y composicion farmaceutica que contiene los mismos. Expired - Lifetime ES2100397T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4222459A DE4222459C2 (de) 1992-07-08 1992-07-08 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten

Publications (1)

Publication Number Publication Date
ES2100397T3 true ES2100397T3 (es) 1997-06-16

Family

ID=6462775

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93110193T Expired - Lifetime ES2100397T3 (es) 1992-07-08 1993-06-25 Espiro(5.5)undecanos 3,9-disubstituidos activos sobre el sistema cardiovascular, proceso para su preparacion y composicion farmaceutica que contiene los mismos.

Country Status (8)

Country Link
US (1) US5444082A (es)
EP (1) EP0578080B1 (es)
JP (1) JPH06239785A (es)
AT (1) ATE152107T1 (es)
DE (2) DE4222459C2 (es)
DK (1) DK0578080T3 (es)
ES (1) ES2100397T3 (es)
GR (1) GR3023595T3 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2018367909B2 (en) 2017-11-17 2022-03-10 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256277A (en) * 1966-06-14 Azaspiro alkanes
BE788490A (fr) * 1971-09-08 1973-01-02 Geschickter Fund Med Res Azaspiranes substitues par du silicium ou du germanium, leur preparation et compositions pharmaceutiques les contenant
US4098823A (en) * 1976-02-11 1978-07-04 Miles Laboratories, Inc. Monospiroalkyl derivatives of prostaglandins
US4737503A (en) * 1986-10-08 1988-04-12 Vipont Laboratories, Inc. Method for inhibiting the release of histamine
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5234922A (en) * 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea

Also Published As

Publication number Publication date
HK1005869A1 (en) 1999-01-29
EP0578080A2 (en) 1994-01-12
DE59306238D1 (de) 1997-05-28
US5444082A (en) 1995-08-22
EP0578080A3 (es) 1994-04-13
JPH06239785A (ja) 1994-08-30
GR3023595T3 (en) 1997-08-29
DE4222459A1 (de) 1994-01-13
ATE152107T1 (de) 1997-05-15
EP0578080B1 (en) 1997-04-23
DK0578080T3 (da) 1997-07-21
DE4222459C2 (de) 1995-09-14

Similar Documents

Publication Publication Date Title
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
MX9303441A (es) Procedimiento para la preparacion de acido clavulanico.
AR016437A1 (es) Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden
FI820061L (fi) Nya karboxylsyraamider deras framstaellning och deras anvaendning saosom laekemedel
ES8707541A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina
ES336645A1 (es) Procedimiento de preparacion de nuevos derivados de la sulfonilurea.
DE3177205D1 (de) Industrielle verbindungen anwendbar als zwischenprodukte in der herstellung von in stellung 2 substituierten 4-hydroxy 3-quinolincarboxamid-derivaten und die herstellung von diesen zwischenprodukten.
ES2063117T3 (es) Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2031894T3 (es) Procedimiento para preparar derivados de 4(3h)-oxo-5,6,7,8-tetrahidropirido-(2,3-d)-pirimidina.
PT96788A (pt) Processo de preparacao de compostos de ureia substituida e de composicoes farmaceuticas
ES2162856T3 (es) Derivados de ergolina serotoninergicos.
DK0578080T3 (da) 3,9-disubstituerede spiro 5.5 undecaner med aktivitet på det cardiovaskulære system, fremgangsmåde til fremstilling af disse og farmaceutisk præparat indeholdende disse
ES2056811T3 (es) Derivados de cinolina, procedimiento para su preparacion y composiciones herbicidas que los contienen.
ES365335A1 (es) Procedimiento para preparar amimocetonas aromaticas.
ES8503652A1 (es) Un procedimiento para la preparacion de un compuesto.
IL89682A0 (en) 5,7-dihydropyrrolo(3,2-f)-benzoxazol-6-ones,processes for the preparation thereof and pharmaceutical compositions containing them
GB1348258A (en) 9-oxo-6.9-dihydro-4h-dioxino-4,5-g-quinolyl-8-carboxylic acids and their isomers, 10-oxo-7,10-dihydro-1h-dioxino-5,4-f-quinolyl- 9-carboxylic acids
FR2383181A2 (fr) Derives de naphtyridine
ES428535A1 (es) Un procedimiento para la preparacion de cicloserina n-sus- tituida.
IT1096815B (it) Derivati della naftiridina
ZA951334B (en) Acronycine analogues a process for their preparation and the pharmaceutical compositions containing them
FR2368955A2 (fr) Derives de la tetrahydro-1,2,3,3a indolo (3,2,1-de) (1,5) naphtyridine
NL7704004A (en) Indolo-(1,5)-naphthyridine derivs. - having antianoxia and psychotropic activities
FR2353550A2 (fr) Procede de preparation de derives de naphtyridine
GB1353513A (en) Streptozotocin derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 578080

Country of ref document: ES